3'-azido-3'-deoxythymidine 5'phosphate has been researched along with lamivudine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mellors, JW; Parikh, UM; Sheen, CW; Sluis-Cremer, N; Torres, PS; Zelina, S | 1 |
Bénech, H; Dehée, A; Dollfus, C; Durand-Gasselin, L; Garbarg-Chenon, A; Grassi, J; Leverger, G; Pruvost, A; Tabone, MD; Vaudre, G | 1 |
2 other study(ies) available for 3'-azido-3'-deoxythymidine 5'phosphate and lamivudine
Article | Year |
---|---|
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Resistance, Multiple, Viral; Genotype; Glutamic Acid; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lysine; Mutagenesis, Site-Directed; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymine Nucleotides; Zidovudine | 2007 |
High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers.
Topics: Anti-HIV Agents; Dideoxynucleotides; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Leukocytes, Mononuclear; Male; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Thymine Nucleotides; Zidovudine | 2008 |